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Boosts the Signal for 
Biomarker Discovery
D
isease processes or exposure to environmental toxicants can 
produce tiny modifications (called adducts) on proteins in the 
blood. A clinical assay that reliably detects those modifications in 
plasma or serum could confirm environmental exposures or speed 
diagnosis of diseases such as cancer. But scientists have identified 
so many protein adducts that might serve as candidate biomarkers 
that finding the best ones to advance into further testing presents a 
major challenge. Advancements in an approach known as shotgun 
proteomics now promise to streamline the discovery process by 
identifying the most promising biomarkers for exploration.
Scientists are still laying the rudiments of a systematic “pipe­
line” for biomarker discovery, says Dan Liebler, a professor of bio­
chemistry, pharmacology, and biomedical informatics at Vanderbilt 
University School of Medicine. Liebler has for almost 10 years used Innovations | Shotgun Proteomics Boosts the Signal for Biomarker Discovery













proteomics to study protein damage caused by oxidative stress or 
chemical toxicity induced by reactive endogenous chemicals. “We 
have knowledge of [reactions or changes] that could be advanced at 
some point to biomarkers, but there are so many candidate changes 
in tissues or living systems exposed to environmental stressors, and 
we don’t have efficient mechanisms for identifying the best possible 
markers to move forward in the pipeline,” Liebler says.
In the last 10 years proteomics technologies involving mass 
spectrometry have made it possible to quickly identify proteins and 
quantify adducts, down to the very amino acid site of modification, 
so scientists can more quickly screen potential biomarkers. In a typi­
cal shotgun proteomics approach, a scientist would take a biologic 
sample, add enzymes to digest all the proteins to peptides, fraction­
ate the peptides, then analyze them on an ion trap massspectrometer. The resulting spectra can 
be compared against peptide databases to 
determine which proteins are present in the 
sample.
Scientists have used the shotgun pro­
teomics approach to discover many pro­
tein modifications of interest. But the 
list of biomarker candidates must be nar­
rowed by determining which ones can be 
reproducibly measured in large numbers 
of clinical samples, such as blood sam­
ples from unexposed and exposed people. 
Performing such tests of candidate bio­
markers currently requires development of 
targeted immunoassays, which is difficult 
and expensive because scientists have to 
develop an antibody for use in the assay 
that is specific to the protein of interest. 
Improvements in mass spectrometry 
assays have the potential to change that. 
Proteomics researchers now predict that in as 
little as three to four years hybrid immuno–
mass spectrometry assays, which combine 
some elements of traditional immunoassays 
with some elements of shotgun proteomics, 
will be used to evaluate candidate bio­
markers in a large number of samples. 
An Assay for Organophosphate 
Exposure
One common proteomic approach to 
identifying biomarkers involves exposing 
an in vitro system to a source of damage 
such as a particular chemical, then using a 
mass spectrometer to identify the protein 
modifications. That is the basic approach 
used by Mike MacCoss, an assistant pro­
fessor of genome sciences at the University 
of Washington, in his research with pro­
fessor of medicine and genome sciences 
Clement Furlong. MacCoss and Furlong 
are searching for biomarkers of exposure 
to organophosphates such as tricresyl 
phosphate, a chemical used as a lubricant 
in jet engines that has been measured in 
aircraft cabin air. When tricresyl phos­
phate is inhaled, it is metabolized into 
toxic cyclic saligenin phosphate. A defini­
tive measure of exposure to this chemical 
could help determine whether such expo­
sure is the source of neurologic symptoms 
such as tremor and memory loss that have 
been reported among airline workers. 
In an attempt to develop an assay for 
organophosphate exposure, MacCoss and 
colleagues use a combination of protein 
biochemistry and proteomics. “The way 
protein biochemistry was done previously 
is that you would have an activity you were 
interested in, or you had an antibody rec­
ognizing a given protein, and as you went 
about purifying your protein, you’d use 
the activity to trace [the protein], and then 
you’d go about determining what your pro­
tein sequence is,” MacCoss says. “We’re 
doing the same thing,” he explains. “It’s 
just that we’re using a mass spectrometer 
on the back end to speed that process up.” 
Organophosphate  compounds  are 
known to inhibit a family of proteins called 
carboxyl  esterases. To find specific proteins 
of interest, MacCoss and colleagues first 
perform activity assays with serum samples 
in vitro. An organophosphate compound is 
added to the sample, then a traditional bio­
chemical activity assay is used to track pro­
teins that are modified by the compound. 
The scientists continue to track activity 
and fractionate the sample until they have 
purified it, meaning it contains only one 
protein. At this point they do not know the 
identity of the protein, but they do know 
that its activity has been modified by the 
addition of the organophosphate. 
Next the researchers use the puri­
fied sample to perform a more targeted 
experiment using microcapillary liquid 
chromatography–tandem mass spectrom­
etry to identify the protein of interest and 
to measure the modifications induced by 
the original organophosphate addition. 
To perform this experiment, they add an 
enzyme such as trypsin to digest the pro­
tein to peptides. “That 
produces a series of over­
lapping  peptides  that 
span the entire protein 
sequence,” MacCoss says. 
The researchers can 
identify both the pro­
tein and the exact sites 
of modification because 
a modification will cause 
a slight shift in the pep­
tide’s mass. Using this 
process, MacCoss and 
colleagues have identi­
fied  three  candidate 
proteins that are modi­
fied by organophosphate 
compounds,  and  they 
have identified the site 
of modification on each 
protein. Now MacCoss—and other scien­
tists who have similarly found candidate 
biomarkers—must test them in a larger 
number of samples, such as tissue or serum 
from exposed individuals. 
Finding the Tiniest Trees in the 
Forest
One major challenge in testing candidate 
biomarkers in vivo is that the modified 
protein will be present in a typical patient 
sample in a very tiny concentration, even 
tinier than in the in vitro experiments. 
“The real challenge is being able to see the 
smaller, less abundant modified proteins 
that are going to be more informative, 
versus the ‘redwoods’—or abundant pro­
teins—that will be everywhere in the forest 
of blood proteins,” says B. Alex Merrick, a 
staff scientist in the NIEHS Laboratory of 
Respiratory Biology. Finding biomarkers 
of specific environmental exposures can be 
especially difficult compared with identi­
fying biomarkers of disease. “A lot of times 
you’re down at the noise level looking for 
changes,” Merrick says. “It’s more difficult 
to prove [modification by exposure].” 
MacCoss tries to address that prob­
lem by making affinity reagents that will 
enrich serum samples for the protein of 
interest without going through the labori­
ous purification used during the in vitro 
experiments. “The affinity reagent will 
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he real challenge [in testing biomarker 
candidates] is being able to see the 
smaller, less abundant modified proteins 
that are going to be more informative, 
versus the “redwoods”—or abundant 
proteins—that will be everywhere in the 
forest of blood proteins.
— B. Alex Merrick
NIEHSpreferentially bind one protein over other 
ones, so you effectively make it so that your 
protein of interest is a greater proportion of 
the total proteins left over in your mixture,” 
he says. “Then we will follow that by a mass 
spectrometry step, and that will allow us to 
make the process much faster.” MacCoss pre­
dicts he will be able to do the affinity enrich­
ment in parallel for many samples at once, and 
then move on to the mass 
spectrometry assay.
Hybrid Assays
Right now, according to 
Liebler, mass spectrom­
etry provides a “bridging 
technology” that can help 
scientists sort through 
bio  marker  possibilities 
without having to devel­
op a high­quality, robust 
assay such as an immuno­
assay  to  evaluate  each 
potential biomarker. But 
evaluating biomarker can­
didates in a large group 
of patient samples still 
requires developing a tar­
geted immunoassay for 
those specific biomarkers. “It’s very hard and 
expensive to make really good antibodies to 
do high­quality ELISAs—the standard plat­
form for immunoassay,” Liebler says.
But Liebler predicts that mass 
spectrometry–based assays could soon 
advance to the point that they are used 
in place of standard immunoassays to 
evaluate biomarkers. “It’s likely that mass 
spectro  metry will be able to take a place 
alongside immunoassays in conducting 
marker trials, as an analytical platform of 
choice,” Liebler says. 
Such a hybrid immuno–mass spec­
trometry assay would use an antibody (the 
“immuno” part) to enrich the blood sample 
for the protein of interest, then the “mass 
spectrometry” part identifies whether the 
protein of interest has been modified and 
to what degree. The hybrid assay would 
still require development of an antibody, 
but the antibody would not need to per­
form at the level required for today’s stan­
dard immunoassays. 
“With a hybrid immuno–mass spec­
trometry assay, the antibody . . . gives the 
mass spectrometry–based detection a boost 
by enriching the target from a very complex 
mixture,” Liebler says. He and others are 
working with such assays in the research 
setting, but Liebler is not aware of work 
with such an assay being published yet in 
the literature. “These assays are really not 
ready for prime time now,” he says. But he 
predicts that within the next three to four 
years they’ll be used in research studies to 
validate biomarkers in large numbers of 
patient samples.
MacCoss has also developed software 
to improve the ability of mass spectrom­
etry to detect the lower­abundance pro­
teins in a sample. In an article published 
in the 3 April 2009 issue of the Journal of 
Proteome Research, for example, MacCoss 
and colleagues described their use of an 
algorithm that programs the mass spec­
trometer to preferentially acquire spectra 
of the peptides that are in lower abun­
dance, writing, “Our approach uses the 
high peak capacity of the mass analyzer 
to resolve and detect peptide features that 
would not normally be sampled in the 
presence of more intense interfering sig­
nals.” MacCoss says, “It’s not perfect, but 
it’s an improvement. It would work for 
a case in which a small fraction of your 
sample contains a modified peptide and 
you had enough material to run the analy­
sis multiple times.”
Another challenge for any future appli­
cation of clinical assays that identify bio­
markers of exposure is that proteins—and 
any modifications that have happened 
because of exposure—might degrade in the 
body before a patient is tested. “As soon as 
a protein becomes degraded, we won’t be 
able to measure the modified form of that 
protein,” MacCoss says. “Some of the pro­
tein biomarkers that we’re following have 
pretty short half­lives. That’s something 
we’ll have to work out when we get there.” 
In the meantime, proteomics researchers 
and their use of hybrid immuno–mass 
spectrometry technologies for identifying 
protein adducts as biomarkers in exposed 
populations may bring us one step closer 
to linking environmental toxicants with 
illness and disease.
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t’s likely that [mass spectrometry–based 
assays] will be able to take a place 
alongside immunoassays in conducting 
marker trials, as an analytical platform 
of choice.
— Dan Liebler
Vanderbilt University School of Medicine
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